CompletedPhase 1ACTRN12607000271404

Immunogenicity and safety of orally administered killed whole cell non-typeable Haemophilus influenzae (Study HI-H003)

A single centre, double blind, placebo controlled, prospective study to assess the immunogenicity and safety of orally administered killed whole cell non-typeable Haemophilus influenzae (NTHi) HI-1-164 in smokers at risk of recurrent bronchitis (Study HI-H003)


Sponsor

The University of Newcastle Research Associates (TUNRA) Ltd

Enrollment

64 participants

Start Date

Jul 25, 2005

Study Type

Interventional

Conditions

Summary

This study monitored safety and measured specific and non-specific immunological parameters in smokers, who are a group at risk of recurrent bronchitis. This group was chosen rather than healthy non-smoking volunteers for this safety/pharmacokinetic study as it was thought possible that the immune parameters may differ in smokers to that in healthy non-smokers. This safety and immunogenicity study has been completed. It was not registered prior to initiation due to our unawareness of the registration system at that time. As it is a Phase I study and is not required to be registered it is being registered for the purpose of public information as we are now aware that post-initiation registration is possible


Eligibility

Sex: Both males and femalesMin Age: 18 YearssMax Age: 65 Yearss

Plain Language Summary

Simplified for easier understanding

This study tests the immune response and safety of an oral vaccine made from killed non-typeable Haemophilus influenzae bacteria, which commonly causes respiratory infections in smokers. It is for adults aged 18 to 65 who smoke at least 10 cigarettes per day and have done so for at least 2 years. Participants take the oral vaccine and have blood tests to check their immune response.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

The test product was formalin-inactivated whole cell non-typeable Haemophilus influenzae formulated in enteric-coated tablets to be taken orally. Each tablet contained 45mg of active ingredient plus e

The test product was formalin-inactivated whole cell non-typeable Haemophilus influenzae formulated in enteric-coated tablets to be taken orally. Each tablet contained 45mg of active ingredient plus excipients. Three courses of tablets were taken by each participant at monthly intervals. Each course consisted of 2 tablets per day for three consecutive days. Thus treatment took place over a period of 60 days. Participants attended visits at 2-week intervals for 3 months.


Locations(1)

Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12607000271404